Which has preferable earnings and valuation, DMRA or SRRK?

Scholar Rock is trading at a lower price-to-earnings ratio than Damora Therapeutics, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Damora Therapeutics, Inc. Common Stock N/A N/A -$209.84M -$3.37 N/A Scholar Rock N/A N/A -$377.94M -$3.45 N/A

Is DMRA or SRRK more profitable?

Scholar Rock's return on equity of -160.19% beat Damora Therapeutics, Inc. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets Damora Therapeutics, Inc. Common Stock N/A -176.39% -77.86% Scholar Rock N/A -160.19% -87.18%

Does the media refer more to DMRA or SRRK?

In the previous week, Scholar Rock had 6 more articles in the media than Damora Therapeutics, Inc. Common Stock. MarketBeat recorded 10 mentions for Scholar Rock and 4 mentions for Damora Therapeutics, Inc. Common Stock. Scholar Rock's average media sentiment score of 1.49 beat Damora Therapeutics, Inc. Common Stock's score of 1.30 indicating that Scholar Rock is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Damora Therapeutics, Inc. Common Stock 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Scholar Rock 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer DMRA or CGON?

In the previous week, CG Oncology had 2 more articles in the media than Damora Therapeutics, Inc. Common Stock. MarketBeat recorded 6 mentions for CG Oncology and 4 mentions for Damora Therapeutics, Inc. Common Stock. CG Oncology's average media sentiment score of 1.55 beat Damora Therapeutics, Inc. Common Stock's score of 1.30 indicating that CG Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Damora Therapeutics, Inc. Common Stock 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CG Oncology 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has preferable earnings & valuation, DMRA or ORKA?

Oruka Therapeutics is trading at a lower price-to-earnings ratio than Damora Therapeutics, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Damora Therapeutics, Inc. Common Stock N/A N/A -$209.84M -$3.37 N/A Oruka Therapeutics N/A N/A -$105.43M -$2.03 N/A

Is DMRA or ORKA more profitable?

Oruka Therapeutics' return on equity of -21.65% beat Damora Therapeutics, Inc. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets Damora Therapeutics, Inc. Common Stock N/A -176.39% -77.86% Oruka Therapeutics N/A -21.65% -20.88%

Which has preferable earnings & valuation, DMRA or COGT?

Cogent Biosciences is trading at a lower price-to-earnings ratio than Damora Therapeutics, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Damora Therapeutics, Inc. Common Stock N/A N/A -$209.84M -$3.37 N/A Cogent Biosciences N/A N/A -$328.94M -$2.16 N/A

Is DMRA or COGT more profitable?

Cogent Biosciences' return on equity of -84.47% beat Damora Therapeutics, Inc. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets Damora Therapeutics, Inc. Common Stock N/A -176.39% -77.86% Cogent Biosciences N/A -84.47% -47.72%

Does the media favor DMRA or COGT?

In the previous week, Cogent Biosciences had 8 more articles in the media than Damora Therapeutics, Inc. Common Stock. MarketBeat recorded 12 mentions for Cogent Biosciences and 4 mentions for Damora Therapeutics, Inc. Common Stock. Cogent Biosciences' average media sentiment score of 1.59 beat Damora Therapeutics, Inc. Common Stock's score of 1.30 indicating that Cogent Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Damora Therapeutics, Inc. Common Stock 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cogent Biosciences 11 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Damora Therapeutics, Inc. Common Stock (DMRA) Competitors

$29.00 -1.60 (-5.23%)

As of 08/28/2026 04:00 PM Eastern

Compare

DMRA vs. SRRK, CGON, ORKA, COGT, and MIRM

Should you buy Damora Therapeutics, Inc. Common Stock stock or one of its competitors? Damora Therapeutics, Inc. Common Stock's main competitors and comparable companies include Scholar Rock (SRRK), CG Oncology (CGON), Oruka Therapeutics (ORKA), Cogent Biosciences (COGT), and Mirum Pharmaceuticals (MIRM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Damora Therapeutics, Inc. Common Stock compare to Scholar Rock?

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) and Scholar Rock (NASDAQ:SRRK) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, dividends, profitability, risk and valuation.

Scholar Rock is trading at a lower price-to-earnings ratio than Damora Therapeutics, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$3.37	N/A
Scholar Rock	N/A	N/A	-$377.94M	-$3.45	N/A

Damora Therapeutics, Inc. Common Stock has a beta of 1.47, meaning that its share price is 47% more volatile than the broader market. Comparatively, Scholar Rock has a beta of 0.69, meaning that its share price is 31% less volatile than the broader market.

Damora Therapeutics, Inc. Common Stock presently has a consensus price target of $44.00, indicating a potential upside of 51.72%. Scholar Rock has a consensus price target of $58.77, indicating a potential upside of 1.68%. Given Damora Therapeutics, Inc. Common Stock's higher possible upside, equities analysts clearly believe Damora Therapeutics, Inc. Common Stock is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.00
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	4 Strong Buy rating(s)	3.13

Scholar Rock's return on equity of -160.19% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Damora Therapeutics, Inc. Common Stock	N/A	-176.39%	-77.86%
Scholar Rock	N/A	-160.19%	-87.18%

14.2% of Damora Therapeutics, Inc. Common Stock shares are held by institutional investors. Comparatively, 91.1% of Scholar Rock shares are held by institutional investors. 0.4% of Damora Therapeutics, Inc. Common Stock shares are held by insiders. Comparatively, 10.3% of Scholar Rock shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Scholar Rock had 6 more articles in the media than Damora Therapeutics, Inc. Common Stock. MarketBeat recorded 10 mentions for Scholar Rock and 4 mentions for Damora Therapeutics, Inc. Common Stock. Scholar Rock's average media sentiment score of 1.49 beat Damora Therapeutics, Inc. Common Stock's score of 1.30 indicating that Scholar Rock is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Damora Therapeutics, Inc. Common Stock	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Scholar Rock	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Scholar Rock beats Damora Therapeutics, Inc. Common Stock on 8 of the 13 factors compared between the two stocks.

How does Damora Therapeutics, Inc. Common Stock compare to CG Oncology?

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) and CG Oncology (NASDAQ:CGON) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, analyst recommendations, dividends, valuation and profitability.

14.2% of Damora Therapeutics, Inc. Common Stock shares are held by institutional investors. Comparatively, 26.6% of CG Oncology shares are held by institutional investors. 0.4% of Damora Therapeutics, Inc. Common Stock shares are held by insiders. Comparatively, 4.8% of CG Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Damora Therapeutics, Inc. Common Stock has a beta of 1.47, suggesting that its share price is 47% more volatile than the broader market. Comparatively, CG Oncology has a beta of 0.23, suggesting that its share price is 77% less volatile than the broader market.

CG Oncology has higher revenue and earnings than Damora Therapeutics, Inc. Common Stock. CG Oncology is trading at a lower price-to-earnings ratio than Damora Therapeutics, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$3.37	N/A
CG Oncology	$4.04M	1,631.06	-$160.99M	-$2.69	N/A

Damora Therapeutics, Inc. Common Stock presently has a consensus price target of $44.00, indicating a potential upside of 51.72%. CG Oncology has a consensus price target of $83.18, indicating a potential upside of 11.89%. Given Damora Therapeutics, Inc. Common Stock's stronger consensus rating and higher probable upside, analysts clearly believe Damora Therapeutics, Inc. Common Stock is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.00
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

Damora Therapeutics, Inc. Common Stock has a net margin of 0.00% compared to CG Oncology's net margin of -3,602.68%. CG Oncology's return on equity of -25.20% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Damora Therapeutics, Inc. Common Stock	N/A	-176.39%	-77.86%
CG Oncology	-3,602.68%	-25.20%	-23.98%

In the previous week, CG Oncology had 2 more articles in the media than Damora Therapeutics, Inc. Common Stock. MarketBeat recorded 6 mentions for CG Oncology and 4 mentions for Damora Therapeutics, Inc. Common Stock. CG Oncology's average media sentiment score of 1.55 beat Damora Therapeutics, Inc. Common Stock's score of 1.30 indicating that CG Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Damora Therapeutics, Inc. Common Stock	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CG Oncology	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

CG Oncology beats Damora Therapeutics, Inc. Common Stock on 10 of the 15 factors compared between the two stocks.

How does Damora Therapeutics, Inc. Common Stock compare to Oruka Therapeutics?

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) and Oruka Therapeutics (NASDAQ:ORKA) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, media sentiment, institutional ownership, dividends and analyst recommendations.

Damora Therapeutics, Inc. Common Stock currently has a consensus price target of $44.00, suggesting a potential upside of 51.72%. Oruka Therapeutics has a consensus price target of $134.30, suggesting a potential upside of 47.36%. Given Damora Therapeutics, Inc. Common Stock's stronger consensus rating and higher probable upside, equities analysts clearly believe Damora Therapeutics, Inc. Common Stock is more favorable than Oruka Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.00
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

14.2% of Damora Therapeutics, Inc. Common Stock shares are owned by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are owned by institutional investors. 0.4% of Damora Therapeutics, Inc. Common Stock shares are owned by insiders. Comparatively, 23.5% of Oruka Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Oruka Therapeutics is trading at a lower price-to-earnings ratio than Damora Therapeutics, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$3.37	N/A
Oruka Therapeutics	N/A	N/A	-$105.43M	-$2.03	N/A

Oruka Therapeutics' return on equity of -21.65% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Damora Therapeutics, Inc. Common Stock	N/A	-176.39%	-77.86%
Oruka Therapeutics	N/A	-21.65%	-20.88%

In the previous week, Oruka Therapeutics had 8 more articles in the media than Damora Therapeutics, Inc. Common Stock. MarketBeat recorded 12 mentions for Oruka Therapeutics and 4 mentions for Damora Therapeutics, Inc. Common Stock. Oruka Therapeutics' average media sentiment score of 1.45 beat Damora Therapeutics, Inc. Common Stock's score of 1.30 indicating that Oruka Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Damora Therapeutics, Inc. Common Stock	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oruka Therapeutics	9 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Damora Therapeutics, Inc. Common Stock has a beta of 1.47, suggesting that its share price is 47% more volatile than the broader market. Comparatively, Oruka Therapeutics has a beta of -0.34, suggesting that its share price is 134% less volatile than the broader market.

Summary

Oruka Therapeutics beats Damora Therapeutics, Inc. Common Stock on 9 of the 13 factors compared between the two stocks.

How does Damora Therapeutics, Inc. Common Stock compare to Cogent Biosciences?

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) and Cogent Biosciences (NASDAQ:COGT) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, media sentiment, institutional ownership, dividends and analyst recommendations.

In the previous week, Cogent Biosciences had 8 more articles in the media than Damora Therapeutics, Inc. Common Stock. MarketBeat recorded 12 mentions for Cogent Biosciences and 4 mentions for Damora Therapeutics, Inc. Common Stock. Cogent Biosciences' average media sentiment score of 1.59 beat Damora Therapeutics, Inc. Common Stock's score of 1.30 indicating that Cogent Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Damora Therapeutics, Inc. Common Stock	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cogent Biosciences	11 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Damora Therapeutics, Inc. Common Stock has a beta of 1.47, suggesting that its share price is 47% more volatile than the broader market. Comparatively, Cogent Biosciences has a beta of 0.38, suggesting that its share price is 62% less volatile than the broader market.

Cogent Biosciences is trading at a lower price-to-earnings ratio than Damora Therapeutics, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$3.37	N/A
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.16	N/A

14.2% of Damora Therapeutics, Inc. Common Stock shares are owned by institutional investors. 0.4% of Damora Therapeutics, Inc. Common Stock shares are owned by insiders. Comparatively, 6.6% of Cogent Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Damora Therapeutics, Inc. Common Stock currently has a consensus price target of $44.00, suggesting a potential upside of 51.72%. Cogent Biosciences has a consensus price target of $49.40, suggesting a potential upside of 42.49%. Given Damora Therapeutics, Inc. Common Stock's stronger consensus rating and higher probable upside, equities analysts clearly believe Damora Therapeutics, Inc. Common Stock is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.00
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.85

Cogent Biosciences' return on equity of -84.47% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Damora Therapeutics, Inc. Common Stock	N/A	-176.39%	-77.86%
Cogent Biosciences	N/A	-84.47%	-47.72%

Summary

Cogent Biosciences beats Damora Therapeutics, Inc. Common Stock on 7 of the 13 factors compared between the two stocks.

How does Damora Therapeutics, Inc. Common Stock compare to Mirum Pharmaceuticals?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, media sentiment, profitability and analyst recommendations.

Mirum Pharmaceuticals has higher revenue and earnings than Damora Therapeutics, Inc. Common Stock. Damora Therapeutics, Inc. Common Stock is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	12.14	-$23.36M	-$14.55	N/A
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$3.37	N/A

Mirum Pharmaceuticals presently has a consensus price target of $137.31, suggesting a potential upside of 40.89%. Damora Therapeutics, Inc. Common Stock has a consensus price target of $44.00, suggesting a potential upside of 51.72%. Given Damora Therapeutics, Inc. Common Stock's stronger consensus rating and higher possible upside, analysts plainly believe Damora Therapeutics, Inc. Common Stock is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.00

Damora Therapeutics, Inc. Common Stock has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -139.18%. Mirum Pharmaceuticals' return on equity of -36.28% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-139.18%	-36.28%	-8.54%
Damora Therapeutics, Inc. Common Stock	N/A	-176.39%	-77.86%

In the previous week, Mirum Pharmaceuticals had 16 more articles in the media than Damora Therapeutics, Inc. Common Stock. MarketBeat recorded 20 mentions for Mirum Pharmaceuticals and 4 mentions for Damora Therapeutics, Inc. Common Stock. Damora Therapeutics, Inc. Common Stock's average media sentiment score of 1.30 beat Mirum Pharmaceuticals' score of 1.27 indicating that Damora Therapeutics, Inc. Common Stock is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	13 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Damora Therapeutics, Inc. Common Stock	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

14.2% of Damora Therapeutics, Inc. Common Stock shares are held by institutional investors. 8.3% of Mirum Pharmaceuticals shares are held by company insiders. Comparatively, 0.4% of Damora Therapeutics, Inc. Common Stock shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Mirum Pharmaceuticals has a beta of 0.52, suggesting that its stock price is 48% less volatile than the broader market. Comparatively, Damora Therapeutics, Inc. Common Stock has a beta of 1.47, suggesting that its stock price is 47% more volatile than the broader market.

Summary

Damora Therapeutics, Inc. Common Stock beats Mirum Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

Get Damora Therapeutics, Inc. Common Stock News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DMRA vs. The Competition

Export

Metric	Damora Therapeutics, Inc. Common Stock	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.79B	$3.93B	$7.20B	$12.90B
Dividend Yield	N/A	3.61%	2.54%	11.28%
P/E Ratio	N/A	11.62	273.16	25.45
Price / Sales	N/A	1,400.24	640.71	89.43
Price / Cash	N/A	106.39	76.74	53.00
Price / Book	-0.26	16.53	12.98	6.14
Net Income	-$209.84M	-$22.80M	$3.48B	$348.86M
7 Day Performance	-5.91%	-0.31%	0.13%	-0.80%
1 Month Performance	-0.72%	9.80%	7.08%	4.13%
1 Year Performance	813.10%	55.66%	24.67%	15.17%

Damora Therapeutics, Inc. Common Stock Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DMRA Damora Therapeutics, Inc. Common Stock	2.8826 of 5 stars	$29.00 -5.2%	$44.00 +51.7%	+813.1%	$1.79B	N/A	N/A	40	Positive News
SRRK Scholar Rock	1.7993 of 5 stars	$58.25 +0.1%	$58.77 +0.9%	+77.0%	$7.09B	N/A	N/A	140	Positive News
CGON CG Oncology	3.2698 of 5 stars	$78.95 +0.9%	$83.18 +5.4%	+177.2%	$6.93B	$4.04M	N/A	61	Positive News
ORKA Oruka Therapeutics	2.8849 of 5 stars	$101.82 -0.6%	$134.30 +31.9%	+515.8%	$6.78B	N/A	N/A	N/A	News Coverage Positive News
COGT Cogent Biosciences	2.8701 of 5 stars	$36.80 +1.6%	$49.40 +34.2%	+187.0%	$6.29B	N/A	N/A	80	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DMRA) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Damora Therapeutics, Inc. Common Stock (DMRA) Competitors

DMRA vs. SRRK, CGON, ORKA, COGT, and MIRM

How does Damora Therapeutics, Inc. Common Stock compare to Scholar Rock?

Summary

How does Damora Therapeutics, Inc. Common Stock compare to CG Oncology?

Summary

How does Damora Therapeutics, Inc. Common Stock compare to Oruka Therapeutics?

Summary

How does Damora Therapeutics, Inc. Common Stock compare to Cogent Biosciences?

Summary

How does Damora Therapeutics, Inc. Common Stock compare to Mirum Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DMRA vs. The Competition

Damora Therapeutics, Inc. Common Stock Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Damora Therapeutics, Inc. Common Stock (DMRA) Competitors

DMRA vs. SRRK, CGON, ORKA, COGT, and MIRM

How does Damora Therapeutics, Inc. Common Stock compare to Scholar Rock?

Which has preferable earnings and valuation, DMRA or SRRK?

Which has more risk & volatility, DMRA or SRRK?

Do analysts prefer DMRA or SRRK?

Is DMRA or SRRK more profitable?

Do institutionals & insiders believe in DMRA or SRRK?

Does the media refer more to DMRA or SRRK?

Summary

How does Damora Therapeutics, Inc. Common Stock compare to CG Oncology?

Do insiders & institutionals believe in DMRA or CGON?

Which has more volatility & risk, DMRA or CGON?

Which has higher earnings & valuation, DMRA or CGON?

Do analysts prefer DMRA or CGON?

Is DMRA or CGON more profitable?

Does the media prefer DMRA or CGON?

Summary

How does Damora Therapeutics, Inc. Common Stock compare to Oruka Therapeutics?

Do analysts rate DMRA or ORKA?

Do insiders and institutionals hold more shares of DMRA or ORKA?

Which has preferable earnings & valuation, DMRA or ORKA?

Is DMRA or ORKA more profitable?

Does the media favor DMRA or ORKA?

Which has more volatility and risk, DMRA or ORKA?

Summary

How does Damora Therapeutics, Inc. Common Stock compare to Cogent Biosciences?

Does the media favor DMRA or COGT?

Which has more volatility and risk, DMRA or COGT?

Which has preferable earnings & valuation, DMRA or COGT?

Do insiders and institutionals hold more shares of DMRA or COGT?

Do analysts rate DMRA or COGT?

Is DMRA or COGT more profitable?

Summary

How does Damora Therapeutics, Inc. Common Stock compare to Mirum Pharmaceuticals?

Which has higher valuation & earnings, MIRM or DMRA?

Do analysts recommend MIRM or DMRA?

Is MIRM or DMRA more profitable?

Does the media refer more to MIRM or DMRA?

Do institutionals and insiders believe in MIRM or DMRA?

Which has more volatility and risk, MIRM or DMRA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DMRA vs. The Competition

Damora Therapeutics, Inc. Common Stock Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools